Review - Beyond Bioethics: Toward a New Biopolitics
By Jordan Liz,
Metapsychology Online Reviews [Review of the book edited by CGS' Osagie K Obasogie and Marcy Darnovsky]
| 09. 04. 2018
From the successful cloning of Dolly the sheep, to the FDA's approval of BiDil as the first race-specific medication to ongoing discussions concerning the use of gene editing technologies such as "CRISPR," medical innovations during the past couple of decades have raised a number of significant ethical, social and political questions. Should cloning as human reproduction be limited? Is the pursuit of race-based medicine morally acceptable? Would it be a moral failure to abstain from using gene-editing technologies if they are proven safe to use? For Osagie K. Obasogie and Marcy Darnovsky, the editors of Beyond Biopolitics: Toward a New Bioethics, these questions are further complicated by the specific sociopolitical context in which they arise. How do we understand, for instance, the FDA's approval of BiDil alongside the history of race and eugenics in the United States? Addressing these questions requires, on their account, a conceptual framework and approach not found in contemporary bioethics.
To elaborate, for Obasogie and Darnovsky, bioethics currently operates on the basis of principlism. Principlism "provides a common framework by embracing four principles as...
Related Articles
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Rob Stein, NPR | 07.16.2025
Scientists can protect children from being born with certain devastating genetic disorders by creating "three-parent" babies, according to the results of a landmark study released Wednesday.
British researchers used the experimental technique to help families have eight children who appear...